Thank you for joining me today to learn about how TEG6S can be utilized within #Anesthesiology. Let's recap on some of the topics that we learned such as specimen collection and transportation, test components, interpretations and more.
👇🏽Follow the #tweetorial below.
First, we reviewed concepts of hemostasis.
Imagine that you cut your hand on a sharp piece of glass, ouch😲
After vasoconstriction, endothelial injury leads to PLT adhesion & aggregation --> the PLT plug.
Release of tissue factor activates coagulation cascade -->fibrin clot
Although we learn these pathways as if they happen sequentially, they are really happening simultaneously. 🔄Platelets are activated by thrombin formation, thrombin formation is activated by platelets.
⁉️What are the traditional coag labs?
🧪That's right. Traditional coagulation testing (PT/PTT) involves plasma based assays that only examine the coagulation factor portion of hemostasis. This doesn't always reflect the patient's TRUE clot or bleeding potential...
👋🏽On the other hand, viscoelastic testing assesses BOTH the cellular + plasma coagulation factor interactions visualizing the ENTIRE clotting process from initiation to lysis. It's primarily used to personalize transfusion management and patient care.
I'm really excited that we have implemented @HaemoneticsCorp TEG6S within @SSMHealthSTL Core Lab area.
This analyzer, developed for point of care testing, is simple and automated and allows for 4 separate tests to be run at one time.
👇🏽Check out this clean & simple design below.
Remember that we have 3 cartridges to run 3 tests
☑️Global hemostasis
☑️Global hemostasis with lysis
✅Platelet Mapping
The samples should be collected using a 21 gauge needle, place tubes in the designated collection bag and send through the pneumatic tube system.
🦶🏽Let's walk through the components of the cartridges...
R value is the time it takes initiate a clot and is measured in minutes.
When prolonged, this can be a sign of bleeding secondary to a factor deficiency and the need to transfuse FFP.
Maximal Amplitude (MA), measured in mm, is the value that describes the clot strength at is maximum potential.
MA CRT: Clot strength with both platelets (80%) and fibrinogen (20%) contribution.
MA FF: Clot strength determined by fibrinogen contribution.
Lysis % 30 (LY30) describes the clot stability describing the fibrinolytic phase, or clot breakdown. If LY30 is increased then we have hyperfibrinolysis. This value is particularly important in the trauma setting when the goal is to STOP the bleed and from and maintain a clot.
To learn more about the topic of viscoelastic testing, I highly recommend reading this great article from @AABB 𝗧𝗿𝗮𝗻𝘀𝗳𝘂𝘀𝗶𝗼𝗻 Journal written by @TimCarll and Dr. Geoff Wool 👉🏽Basic principles of viscoelastic testing. onlinelibrary.wiley.com/doi/10.1111/tr…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#SLUSOMPath24
In our final week, we focused on #HemodynamicDisorders including #edema, hemostasis, infarction, thrombosis and shock. Let’s recap on these concepts and study for the exam 👇🏽Follow #Tweetorial below.
#Edema is a condition in which there is increased fluid in the interstitial extravascular space. Vascular hydrostatic pressure & plasma osmotic pressure are factors that control movement between vascular & interstitial spaces. How does a deep venous thrombus (#DVT) cause edema?
👍🏽You got it. A #DVT causes venous blockage, and therefore leads to increased hydrostatic pressure DISTAL to the site of the thrombus. This causes edema to the areas dependent on the blocked vein for drainage. Check out the symptoms of #DVT here👇🏽
#SLUSOMPath24.
Week #2 Dr. Miller covered topics of Neoplasia.
Let's take a few minutes to review the material and study for the exam.
👇🏽Follow the #Tweetorial below.
Neoplasia can divided into benign and malignant processes.
⁉What is the main feature that can separate the two?
That's right. The main feature that distinguishes between benign + malignant is the potential to invade basement membrane + metastasize or spread through blood or lymphatics to distant sites.
👇🏽This fibrosarcoma has all the features of malignant.
#SLUSOMPath24, 😀👏🏽Congratulations on completing your first week of Introduction to Pathology. Let's review some of the concepts you learned with Dr. Brink as you head into Week #2 and we begin to discuss #Neoplasia.
Follow the #Tweetorial below.
When a person develops chronic hypertension, strain can develop on the heart leading to an increase in mechanical work load. Cardiac myocytes (heart muscle fibers) grow in size to accommodate.
⁉️This cellular adaptive change is called?
🙌🏽You got it. Hypertrophy occurs when cells increase in their size which primarily occurs with myocytes. On the other hand, hyperplasia is when cells increase in number. Here’s an example of cardiac hypertrophy. Notice how thickened the cardiac walls and muscle fibers appear 👉🏽
Thank you for joining me to today for the @SSMHealthSTL Pediatric Education Webinar Series where we discussed the topic of 🩸👶🏾Pediatric Patient Blood Management.
From our rural hospitals to large academic ones, together let's optimize pediatric & neonatal care.
👇🏽 #Blooducation
Coming out of #WorldBloodDonorDay, it was perfect timing to discuss this topic as we celebrate our incredible blood donors while bringing awareness of the need to collect and transfuse safe blood to our patients, many which are so 🖐️🏽tiny, fitting within the palm of our hand.
💎Blood is a precious resource.
⚖️Blood transfusions have risks.
"Transfusing the right product, in the right dose, to the right patient, at the right time" is the fundamental concept of Patient Blood Management.
How do we apply these concepts within the pediatric setting?
🌟Just released! Outstanding @bloodbankguy 🎧podcast w/ Dr. Sujit Sheth. Comprehensive discussion on transfusion-dependent #thalassemia focusing on pathogenesis, terminology & role of transfusion support. Listen now for CE credit.
For the pearls, follow the #Tweetorial below👇🏽
Derived from the Greek word “thal” or sea🌊thalassemia known as Mediterranean anemia, is an anemia affecting 1.5% of the world population along the “thalassemia belt” extending from the Mediterranean, the Middle East, India, SoutheastAsia, up to China. Like SCD, thalassemias are:
Thalassemias are also hereditary and may offer protection against malaria. However, unlike #sicklecelldisease which results in qualitative Hb defects, thalassemia causes a quantitative defects in either Hb α or β chains causing both ineffective erythropoiesis and anemia.